Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Triamcinolone vs Candida Antigen in Alopecia Areata
NCT06564805Recruiting
- Sponsor
- Universidad Autónoma de Nuevo León
- Start
- Aug 2024
- Primary completion
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of candida albicans antigen in alopecia areata (2 arms), sponsored by Universidad Autónoma de Nuevo León. Primary endpoint: Treatment response at 5 months. Started Aug 2024; status: recruiting.
02
Drugs
candida albicans antigen
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT06564805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564805.